ESTRO 2025 - Abstract Book

S2124

Clinical - Urology

ESTRO 2025

Conclusion: Adaptive radiotherapy with 36Gy/6F delivered on an MR-Linac appears to be a well-tolerated treatment for fragile patients with local or locally advanced bladder cancer who are not candidates for standard curative treatment. The local control rate at 3 months is clinical relevant. It’s desirable to have a better selection of the patients to avoid overtreatment of those who die early and to identify candidates for trials with accelerated and dose-escalated radiotherapy for better long-term local control.

Keywords: Bladder cancer, hypofractionation, MR Guided RT

References: 1 Huddart et al. ”Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the Day treatment in patients receiving Ultra- hypofractionated Weekly Radiation Therapy for Bladder Cancer” 2 Hafeez et al. “Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment”

4345

Digital Poster Efficacy and toxicity study of Stereoataxic body radiotherapy (SBRT) in prostate cancer ANGIE Y RAMOS DE LOS RIOS, ROCIO D PEREZ OROZCO, FERNANDO M JARAMILLO OCHARAN, MARIA CALDERÓ

TORRA, SEHILA LARRAYAD SANZ, MARIA C VELILLA MILLÁN, LUIS SOPEÑA SANZ ONCOLOGIA RADIOTERAPICA, HOSPITAL CLINICO LOZANO BLESA, ZARAGOZA, Spain

Purpose/Objective: Stereoataxic body radiotherapy (SBRT) is an extreme form of hypofractionation. The aim of this study is to analyze the toxicity of SBRT in the treatment of prostate cancer.